SHANGHAI – Lee's Pharmaceutical, of Hong Kong, has licensed from Ikaria Inc., of Hampton, N.J., the rights for Inomax, an inhaled nitric oxide that treats hypoxic respiratory failure (HRF) in newborns of 34 weeks gestational age. This follows Lee's successful strategy of licensing products that go after unmet medical needs in China and strengthens the firm's position in pediatric and critical care drugs.